Safety and Efficacy Results of Retreatment With a PARP Inhibitor Monotherapy in Late-Line Recurrent Ovarian Cancer: Results From a Subset of the QUADRA Trial
2020
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI